Med pipeline analysis: enumerate a biotech/pharma company's drug/device assets by phase, indication, and next catalyst, with risk-adjusted value framing and cash-runway assessment. The core valuation lens for clinical-stage names.
Scanned 9/7/2026
Install to Claude Code
npx -y skills add agentii-ai/agentii-investment-intelligence --skill pipeline-analysis --agent claude-codeInstalls into .claude/skills of the current project.
Are you the author of Pipeline Analysis?
Add the live security badge to your README — it updates automatically with every re-scan.
[](https://www.skillsdirectory.com/skills/agentii-ai-pipeline-analysis)More formats (shields.io, HTML) on the badges page.
---
name: pipeline-analysis
description: "Med pipeline analysis: enumerate a biotech/pharma company's drug/device assets by phase, indication, and next catalyst, with risk-adjusted value framing and cash-runway assessment. The core valuation lens for clinical-stage names."
multi_ticker_semantics: single_target
temporal_scope:
default_quarters: 4
max_quarters: 8
description: "Catalyst window default 4 quarters; up to 8 for long-horizon pipeline mapping."
allowed_tools:
- get_company_drugs
- get_company_devices
- search_universe_drugs
- search_universe_devices
- search_companies
- search_sec_filings
- search_documents
- read_source_outline
- read_source_pages
- search_xbrl_facts
- search_investment_cases
- get_investment_case
- search_investment_strategies
- get_investment_strategy
- search_by_analogue
- search_knowledge_entries
- get_knowledge_entry
retrieval_scope: unstructured_document_search
min_tool_diversity: 3
parameter_free: false
---
> Methodology inspired by publicly taught pipeline-valuation frameworks; all text is an original paraphrase.
## Defaults
| Parameter | Default Value | Rationale |
|-----------|---------------|-----------|
| asset_scope | all disclosed assets | Full-pipeline enumeration first |
| include_devices | true | Devices via PMA/De Novo share catalyst logic |
| valuation_frame | risk-adjusted | rNPV-style thinking, not raw NPV |
## Preflight
Run canonical pre-flight per `contracts/preflight.md`. Propagate X-Agentii-Trace per `contracts/x-agentii-trace-header.md`.
## Triggers
- "Analyze [biotech ticker]'s pipeline."
- "What's in [ticker]'s clinical portfolio?"
- "Map [ticker]'s assets by phase and indication."
- "What are [ticker]'s next catalysts?"
- "How much runway does [ticker] have?"
- "Risk-adjusted view of [ticker]'s pipeline value."
- "Which of [ticker]'s programs matter most?"
- "Pipeline deep-dive for [ticker]."
- "What devices does [ticker] have in the works?"
- "Compare [ticker]'s pipeline to its peers."
## Production Grounding
- Enumerate assets from `get_company_drugs`/`get_company_devices` (049 universes); supplement with filings (`search_sec_filings`, `read_source_*`) for trial phase/status.
- Phase-aware valuation: discovery/preclinical minimal; P1/P2 option-value; P3/registered majority of risk-adjusted value. Apply AdCom-style scrutiny axes when sizing pivotal-stage assets (per `references/knowledge-frameworks.md`).
- Cash runway (quarters) gates which catalysts the company can reach; funding risk is pipeline risk.
## Data Source Priority
1. `get_company_drugs` / `get_company_devices` — asset inventory from the 049 universes.
2. `search_sec_filings` / `read_source_*` — phase, status, trial data, guidance.
3. `search_xbrl_facts` — cash/R&D spend for runway.
4. Knowledge layer: `search_investment_strategies(sectors=med)` + cases for playbook grounding.
## Methodology
### Retrieval Scope
unstructured_document_search
### Retrieval Strategy
1. Pull asset inventory (`get_company_drugs`/`get_company_devices`).
2. Enrich per-asset phase/status/next-catalyst from filings.
3. Compute runway from balance-sheet facts.
4. Size each asset risk-adjusted; ground in strategies/cases.
### Temporal Scope
See frontmatter temporal_scope block.
### Tool Allowlist
See frontmatter allowed_tools.
### Protocol
1. Asset enumeration
2. Phase/status enrichment
3. Runway assessment
4. Risk-adjusted synthesis
## Modes
- **Full pipeline** (default): all assets with catalysts.
- **Value-drivers**: only the top risk-adjusted assets.
- **Runway-focused**: funding-requirement analysis.
## Tool Fallbacks
| Failure | Fallback |
|---------|----------|
| get_company_drugs empty | Reconstruct from filings keyword search; annotate coverage_gap |
| No cash data | Flag runway unavailable |
| Knowledge tools empty | Proceed with structured data only |
## Output File
`{ticker}/{YYYY-MM-DD_HHMM}_pipeline-analysis_{affix}.md`
## Output Structure
1. **Executive Summary** — pipeline stance in 2-3 sentences
2. **Asset Table** — phase, indication, next catalyst, risk-adjusted sizing
3. **Value Drivers** — top assets with scrutiny-axes assessment
4. **Runway & Funding** — quarters of cash, funding needs
5. **Historical Context** — strategies/cases with /v/ citations
6. **Coverage Gaps** — degraded flags
## Error Handling
| Error | Fallback |
|-------|----------|
| Phase unknown | Mark "undisclosed"; do not guess |
| No catalysts found | Say so explicitly; note pipeline may be early-stage |
## Memory Load
See `contracts/memory-load.md`.
## Snapshot
See `contracts/snapshot-synthesis.md`.
## Final Summary (TUI)
Include ### Key Citations block with 0-10 clickable /v/ URLs.
## References
- `contracts/citation-and-memory.md`
- `contracts/output-frontmatter-schema.md`
- `contracts/memory-load.md`
- `contracts/snapshot-synthesis.md`
- `contracts/preflight.md`
- `references/knowledge-frameworks.md`
Is this your skill, or is something wrong with this listing? Request removal or report an issue. Author removals are honored within 72 hours.
No comments yet. Be the first to comment!